Crizotinib may also be a suitable drug to increase the sensitivity of DLBCL cells to R-CHOP treatment, so in addition to the R-CHOP regimen, crizotinib/EMT pathway will likely be a new idea for the treatment of non-Hodgkin lymphoma. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.